Inhibition of hepatic and cutaneous biotransformation of resorufin ethers following intraperitoneal administration of 1-aminobenzotriazole.
Oldfield
N F
NF
Department of Drug Metabolism, Hoffmann-La Roche, Nutley, New Jersey 07110.
Mortillo
M
M
Garland
W A
WA
Mico
B A
BA
D000818:Animals; D001711:Biotransformation / Q000187:drug effects; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003640:Dealkylation; D004987:Ethers / Q000493:pharmacokinetics; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism*; D010078:Oxazines / Q000378:metabolism / Q000493:pharmacokinetics*; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology*
D004987:Ethers; D010078:Oxazines; D014230:Triazoles; C033020:1-aminobenzotriazole; C014180:resorufin; D003577:Cytochrome P-450 Enzyme System